Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 131 - 140 of 333

<< Previous | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | Next >>

Last updated: 20th February 2008

Patent No.: US 6713078
Retrocyclins: antiviral and antimicrobial peptides.
Applicant: Lehrer RI, Waring AJ, Cole AM, Hong TB (2004)
Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.

Patent No.: US 6680058
Compositions and methods for contraception in or sterilization of mammals.
Applicant: Enright FM, Jaynes JM, Hansel W, Melrose PA, Elzer PH (2004)
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The lytic peptide tested was hecate, a synthetic peptide analog of melittin.

Patent No.: US 6677503
Sunflower anti-pathogene proteins and genes and their uses.
Applicant: Bidney DL, Duvick J, Hu X, Lu G, Crasta OR (2004)
The invention relates to isolated sunflower nucleic acid sequences encoding a protein having antipathogenic activity, vectors, plant cells, plants and seeds comprising said nucleic acid sequences. The invention further relates to a method of transforming plants for increased resistance against plant pathogens.

Patent No.: US 6677431
Design, preparation, and properties of antibacterial beta-peptides.
Applicant: DeGrado WF, Hamuro Y, Liu D (2004)
An antibacterial beta-peptide having the following formula: ##STR1## wherein R.sub.1 is H, an alkyl group including 1-4 carbon atoms, phenyl, heteroaryl, or an alkyl-aryl; R.sub.2 is an amine-containing alkyl group having the formula --(CH.sub.2).sub.m NH.sub.2, wherein m=1, 2, 3, 4, or 5, (CH.sub.2).sub.x NHC.dbd.NHNH.sub.2 wherein x is 1, 2, 3, 4, or 5, a pyridyl, an alkylpryidyl, an amidine-substituted benzyl, a phenyl group, or a cyclic amidine; R.sub.3 is H, an alkyl group including 1-4 carbon atoms, phenyl, heteroaryl, or an alkyl-aryl; X is --NH.sub.2, --OH, --NHR, or OR where R is alkyl, aryl or acyl groups either free or polymer-supported, a carboxamide, a substituted carboxamide, or a polymer; Y is H, an alkyl group, an acyl group, an acyl-terminated polymer, a sulphonamide, an ether, a urea, a urethane, or a polymer; and n is 2, 3, 4, 5, 6, or 7.

Patent No.: US 265337
Method of generating an immune response using vaccine compositions that are resistant to antimicrobial action of human defensins.
Applicant: Zsebo KM, Ballester R, Schoolnik G, Julio SM., Giusti AF (2004)
The disclosed invention provides immunogenic compns. contg. attenuated bacteria (such as Salmonella enterica) which are resistant to the antimicrobial actions of human defensins, particularly human defensin 5 (HD-5). Methods for using these compns. to elicit a sustained and highly specific immune response are provided. The invention also provides methods for prepg. vaccines wherein a heterologous antigen is expressed by the defensin-resistant bacteria.

Patent No.: US 210018
Modified dental prosthesis comprising phosphate-containing polymers.
Applicant: Periathamby AR, Dentino AR (2004)
Phosphate-contg. co-polymers useful for making denture bases, denture liners and tissue conditioners with phosphate anion-charged surfaces are disclosed. The phosphate anions enable the denture bases, denture liners and tissue conditioners to adsorb cationic antimicrobial mols. Dentures, denture bases materials, denture liners and tissue conditioners made of the above co-polymers are also disclosed. Further disclosed are methods for synthesizing the co-polymer(s) and for making the denture bases, denture liners and tissue conditioners. Me methacrylate-methallyl phosphate copolymer was prepd. Histatin was adsorbed on the above polymer and tested for adherence of Candida albicans. Adherence of C. albicans to the polymer surface was inhibited.

Patent No.: US 180094
Activation agents on the surface of encapsulation vesicles.
Applicant: Joyce TH (2004)
The present invention relates to a compn. and method for therapeutic treatment of humans and other mammals. The present invention may address drug resistance problems in vivo. The therapeutic compn. of the present invention comprises an encapsulation vesicle, an activation agent such as a pore forming agent on the surface of the encapsulation vesicle and an optional targeting ligand. The targeting ligand may be attached to either the activation agent or the encapsulation vesicle. The encapsulation vesicle may contain a bioactive agent that may be released to the inside of a diseased cell. The activation agent or pore forming agent is activated by an activation condition. The method for therapeutic treatment includes contacting a cell membrane with a therapeutic compn. that has an encapsulation vesicle and an activation agent such as a pore forming agent on the surface of the encapsulation vesicle and allowing the cell membrane to incorporate the therapeutic compn. so that the activation agent or pore forming agent of the therapeutic compn. may be activated by an activation condition.

Patent No.: US 063123
Mutations in human beta defensin 2 gene promoter associated with increased susceptibility to periodontal disease and methods for diagnosis.
Applicant: Abiko Y, Kaku T, Arakawa T, Takuma T, Nishimura M, Kusano K (2004)
Methods for detecting mutations in beta defensin 2 gene promoter assocd. with increased susceptibility to periodontal disease are provided. Sequence homol. between DNA derived from a defensin gene promoter existing in a sample obtained from the gingival tissues of a subject and a nucleotide sequence comprising a mutation site in the promoter region, and/or compatibility in PCR amplification, are detd. Thereby a gene mutation is detected and then the site of the gene mutation is detd., so that data for the estn. can be collected.

Patent No.: US 014669
Antimicrobial theta defensins, analogs thereof, and methods of use.
Applicant: Selsted ME, Tran DQ (2004)
The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amt. of a theta defensin analog to the environment, thereby reducing or inhibiting the growth or survival of the microorganism. The structure and microbicidal activities and relationships of theta defensins and protegrin-1 were evaluated by comparing the microbicidal activities of 20 analogs against Escherichia coli, Candida albicans, and Cryptococcus neoformans and by detg. the relative bactericidal activities in assays contg. ionic and serum additives.

Patent No.: US 219612
Methods for detecting intracellular defensins in various leukocyte subpopulations.
Applicant: D'Costa SS (2004)
The present invention relates to methods and kits for detg. intracellular defensin expression in specific leukocyte subpopulations by flow cytometry. Specific leukocyte subpopulations may be identified by measuring the signals generated from one or more cell-distinguishing antibodies bound to cells in a sample. Intracellular defensin expression in specific leukocyte subpopulations may be detd. by measuring the signals generated from one or more defensin-specific antibodies bound to defensin inside the cells. These methods may be used to generate an intracellular defensin expression profile which may be useful for diagnosing and treating diseases and illnesses.